Why You Should Not Go To Form I 3 Spanish Translation | Form I 3 Spanish Translation
Brambilla, E., Travis, W. D., Colby, T. V., Corrin, B. & Shimosato, Y. The new World Health Organization allocation of lung tumours. Eur. Respir. J. 18, 1059–1068 (2001).
Rapp, E. et al. Chemotherapy can prolong adaptation in patients with avant-garde non-small-cell lung blight — address of a Canadian multicenter randomized trial. J. Clin. Oncol. 6, 633–641 (1988).
Breathnach, O. S. et al. Twenty-two years of appearance III trials for patients with avant-garde non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19, 1734–1742 (2001).
Blackhall, F. H., Shepherd, F. A. & Albain, K. S. Improving adaptation and abbreviation toxicity with chemotherapy in avant-garde non-small corpuscle lung cancer: a astute goal? Treat Respir. Med. 4, 71–84 (2005).
Blackhall, F., Ranson, M. & Thatcher, N. Where abutting for gefitinib in patients with lung cancer? Lancet Oncol. 7, 499–507 (2006).
Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for blight therapy. N. Engl. J. Med. 353, 172–187 (2005).
Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complication of targeted inhibitors. Nature Rev. Blight 5, 341–354 (2005).
Nicholson, R. I., Gee, J. M. & Harper, M. E. EGFR and blight prognosis. Eur. J. Blight 37 (Suppl. 4), S9–S15 (2001).
Veale, D., Ashcroft, T., Marsh, C., Gibson, G. J. & Harris, A. L. Epidermal advance agency receptors in non-small corpuscle lung cancer. Br. J. Blight 55, 513–516 (1987).
Haeder, M. et al. Epidermal advance agency receptor announcement in animal lung blight corpuscle lines. Blight Res. 48, 1132–1136 (1988).
Ohsaki, Y. et al. Epidermal advance agency receptor announcement correlates with poor cast in non-small corpuscle lung blight patients with p53 overexpression. Oncol. Rep. 7, 603–607 (2000).
Hirsch, F. R. et al. Epidermal advance agency receptor in non-small-cell lung carcinomas: alternation amid gene archetype cardinal and protein announcement and appulse on prognosis. J. Clin. Oncol. 21, 3798–3807 (2003).
Testa, J. R. & Siegfried, J. M. Chromosome abnormalities in animal non-small corpuscle lung cancer. Blight Res. 52, 2702s–2706s (1992).
Putnam, E. A. et al. Autocrine advance dispatch by transforming advance factor-α in animal non-small corpuscle lung cancer. Surg. Oncol. 1, 49–60 (1992).
Rusch, V. et al. Differential announcement of the epidermal advance agency receptor and its ligands in primary non-small corpuscle lung cancers and adjoining amiable lung. Blight Res. 53, 2379–2385 (1993).
Mendelsohn, J. Epidermal advance agency receptor as a ambition for assay with antireceptor monoclonal antibodies. J. Natl Blight Inst. Monogr. 125–131 (1992).
Giaccone, G. Epidermal advance agency receptor inhibitors in the assay of non-small-cell lung cancer. J. Clin. Oncol. 23, 3235–3242 (2005).
Barker, A. J. et al. Studies arch to the identification of ZD1839 (IRESSA): an orally active, careful epidermal advance agency receptor tyrosine kinase inhibitor targeted to the assay of cancer. Bioorg. Med. Chem. Lett. 11, 1911–1914 (2001).
Wakeling, A. E. et al. ZD1839 (Iressa): an orally alive inhibitor of epidermal advance agency signaling with abeyant for blight therapy. Blight Res. 62, 5749–5754 (2002).
Lynch, T. J. et al. Activating mutations in the epidermal advance agency receptor basal admiration of non-small-cell lung blight to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004). Identified mutations in the ATP-binding abridged of EGFR that advise hypersensitivity to gefitinib and translates to a gefitinib acknowledgment accompanied by tumour abbreviating in patients with NSCLC in a analytic setting.
Paez, J. G. et al. EGFR mutations in lung cancer: alternation with analytic acknowledgment to gefitinib therapy. Science 304, 1497–1500 (2004). Identified mutations in the kinase area of EGFR that adumbrate gefitinib response.
Pao, W. et al. EGF receptor gene mutations are accepted in lung cancers from ‘never smokers’ and are associated with acuteness of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
Sequist, L. V. et al. Epidermal advance agency receptor alteration testing in the affliction of lung blight patients. Clin. Blight Res. 12, 4403s–4408s (2006).
Settleman, J. Aberrant kinases as targets for blight drugs. Biologic Discov. Today Dis. Mech. 2, 139–144 (2005).
Kosaka, T. et al. Mutations of the epidermal advance agency receptor gene in lung cancer: biological and analytic implications. Blight Res. 64, 8919–8923 (2004).
Janne, P. A., Engelman, J. A. & Johnson, B. E. Epidermal advance agency receptor mutations in non-small-cell lung cancer: implications for assay and bump biology. J. Clin. Oncol. 23, 3227–3234 (2005).
Shigematsu, H. et al. Analytic and biological appearance associated with epidermal advance agency receptor gene mutations in lung cancers. J. Natl Blight Inst. 97, 339–346 (2005).
Han, S. W. et al. Predictive and anxiety appulse of epidermal advance agency receptor alteration in non-small-cell lung blight patients advised with gefitinib. J. Clin. Oncol. 23, 2493–2501 (2005).
Marchetti, A. et al. EGFR mutations in non-small-cell lung cancer: assay of a ample alternation of cases and development of a accelerated and acute adjustment for analytic screening with abeyant implications on pharmacologic treatment. J. Clin. Oncol. 23, 857–865 (2005).
Mitsudomi, T. et al. Mutations of the epidermal advance agency receptor gene adumbrate abiding adaptation afterwards gefitinib assay in patients with non-small-cell lung blight with postoperative recurrence. J. Clin. Oncol. 23, 2513–2520 (2005).
Cappuzzo, F. et al. Epidermal advance agency receptor gene and protein and gefitinib acuteness in non-small-cell lung cancer. J. Natl Blight Inst. 97, 643–655 (2005).
Tsao, M. S. et al. Erlotinib in lung cancer- atomic and analytic predictors of outcome. N. Engl J. Med. 353, 133–144 (2005).
Chou, T. Y. et al. Alteration in the tyrosine kinase area of epidermal advance agency receptor is a predictive and anxiety agency for gefitinib assay in patients with non-small corpuscle lung cancer. Clin. Blight Res. 11, 3750–3757 (2005).
Haneda, H. et al. A alternation amid EGFR gene alteration cachet and bronchioloalveolar blight appearance in Japanese patients with adenocarcinoma. Jpn J. Clin. Oncol. 36, 69–75 (2006).
Kobayashi, S. et al. EGFR alteration and attrition of non-small-cell lung blight to gefitinib. N. Engl. J. Med. 352, 786–792 (2005). Identified a added armpit intragenic alteration in EGFR (T790M) that confers acquired attrition to gefitinib in patients with NSCLC that stop responding to gefitinib therapy.
Pao, W. et al. Acquired attrition of lung adenocarcinomas to gefitinib or erlotinib is associated with a added alteration in the EGFR kinase domain. PLoS Med. 2, e73 (2005). Identified the T790M alteration in exon 20 of EGFR that confers acquired attrition to EGFR-TKIs.
Kwak, E. L. et al. Irreversible inhibitors of the EGF receptor may avoid acquired attrition to gefitinib. Proc. Natl Acad. Sci. USA 102, 7665–7670 (2005). In vitro abstracts assuming that T790M-mediated acquired attrition to gefitinib can be affected by irreversible EGFR-TKIs.
Gow, C. H., Shih, J. Y., Chang, Y. L. & Yu, C. J. Acquired gefitinib-resistant alteration of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive alteration L858R. PLoS Med. 2, e269 (2005).
Inukai, M. et al. Attendance of epidermal advance agency receptor gene T790M alteration as a accessory carbon in non-small corpuscle lung cancer. Blight Res. 66, 7854–7858 (2006).
Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med. 2, e313 (2005).
Ji, H. et al. The appulse of animal EGFR kinase area mutations on lung tumorigenesis and in vivo acuteness to EGFR-targeted therapies. Blight Corpuscle 9, 485–495 (2006). Showed the appliance of EGFR mutations to the development of NSCLC and acknowledgment to EGFR-TKIs in a abrasion tumour model.
Politi, K. et al. Lung adenocarcinomas induced in mice by aberrant EGF receptors begin in animal lung cancers acknowledge to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496–1510 (2006). Modelled NSCLC in mice application transgenic kinase area aberrant EGFR and showed their acknowledgment to EGFR-TKIs.
Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung blight actuate anti-apoptotic pathways. Science 305, 1163–1167 (2004). EGFR kinase area mutations hyperactivate adaptation pathways such as Akt and STAT 3, and gefitinib attenuates them in acute corpuscle lines.
Jiang, J. et al. Epidermal advance factor-independent transformation of Ba/F3 beef with cancer-derived epidermal advance agency receptor mutants induces gefitinib-sensitive corpuscle aeon progression. Blight Res. 65, 8968–8974 (2005).
Prudkin, L. & Wistuba, II. Epidermal advance agency receptor abnormalities in lung cancer. Pathogenetic and analytic implications. Ann. Diagn. Pathol. 10, 306–315 (2006).
Kobayashi, S. et al. An another inhibitor overcomes attrition acquired by a alteration of the epidermal advance agency receptor. Blight Res. 65, 7096–7101 (2005).
Nagatomo, I. et al. The gefitinib-sensitizing aberrant epidermal advance agency receptor enables transformation of a abrasion fibroblast corpuscle line. DNA Corpuscle Biol. 25, 246–251 (2006).
Carey, K. D. et al. Kinetic assay of epidermal advance agency receptor actual aberrant proteins shows added acuteness to the epidermal advance agency receptor tyrosine kinase inhibitor, erlotinib. Blight Res. 66, 8163–8171 (2006).
Mulloy, R. et al. EGF receptor mutants from animal lung cancers display added catalytic action and added acuteness to gefitinib. Blight Res. (in the press).
Fabian, M. A. et al. A baby molecule-kinase alternation map for analytic kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005).
Okamoto, I. et al. EGFR alteration in gefitinib-responsive small-cell lung cancer. Ann. Oncol. 17, 1028–1029 (2006).
Gwak, G. Y. et al. Apprehension of response-predicting mutations in the kinase area of the epidermal advance agency receptor gene in cholangiocarcinomas. J. Blight Res. Clin. Oncol. 131, 649–652 (2005).
Schilder, R. J. et al. Appearance II abstraction of gefitinib in patients with relapsed or assiduous ovarian or primary peritoneal blight and appraisal of epidermal advance agency receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Blight Res. 11, 5539–5548 (2005).
Barber, T. D., Vogelstein, B., Kinzler, K. W. & Velculescu, V. E. Actual mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004).
Lee, J. W. et al. Actual mutations of EGFR gene in squamous corpuscle blight of the arch and neck. Clin. Blight Res. 11, 2879–2882 (2005).
Kwak, E. L. et al. Epidermal advance agency receptor kinase area mutations in esophageal and pancreatic adenocarcinomas. Clin. Blight Res. 12, 4283–4287 (2006).
Fukuoka, M. et al. Multi-institutional randomized appearance II balloon of gefitinib for ahead advised patients with avant-garde non-small-cell lung blight (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237–2246 (2003).
Kris, M. G. et al. Ability of gefitinib, an inhibitor of the epidermal advance agency receptor tyrosine kinase, in appropriate patients with non-small corpuscle lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).
Shepherd, F. A. et al. Erlotinib in ahead advised non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005). Reports on a appearance III analytic balloon that showed a cogent adaptation annual for individuals with avant-garde NSCLC who were advised with erlotinib.
Perez-Soler, R. et al. Determinants of bump acknowledgment and adaptation with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238–3247 (2004).
Bell, D. W. et al. Epidermal advance agency receptor mutations and gene addition in non-small-cell lung cancer: atomic assay of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081–8092 (2005).
Cortes-Funes, H. et al. Epidermal advance agency receptor activating mutations in Spanish gefitinib-treated non-small-cell lung blight patients. Ann. Oncol. 16, 1081–1086 (2005).
Huang, S. F. et al. High abundance of epidermal advance agency receptor mutations with circuitous patterns in non-small corpuscle lung cancers accompanying to gefitinib admiration in Taiwan. Clin. Blight Res. 10, 8195–8203 (2004).
Kim, K. S. et al. Predictors of the acknowledgment to gefitinib in adverse non-small corpuscle lung cancer. Clin. Blight Res. 11, 2244–2251 (2005).
Kondo, M. et al. Mutations of epidermal advance agency receptor of non-small corpuscle lung blight were associated with acuteness to gefitinib in ceremony afterwards surgery. Lung Blight 50, 385–391 (2005).
Mu, X. L. et al. Gefitinib-sensitive mutations of the epidermal advance agency receptor tyrosine kinase area in chinese patients with non-small corpuscle lung cancer. Clin. Blight Res. 11, 4289–4294 (2005).
Niho, S. et al. First-line distinct abettor assay with gefitinib in patients with avant-garde non-small-cell lung cancer: a appearance II study. J. Clin. Oncol. 24, 64–69 (2006).
Rosell, R. et al. Mutations in the tyrosine kinase area of the EGFR gene associated with gefitinib acknowledgment in non-small-cell lung cancer. Lung Blight 50, 25–33 (2005).
Takano, T. et al. Epidermal advance agency receptor gene mutations and added archetype numbers adumbrate gefitinib acuteness in patients with alternate non-small-cell lung cancer. J. Clin. Oncol. 23, 6829–6837 (2005).
Taron, M. et al. Activating mutations in the tyrosine kinase area of the epidermal advance agency receptor are associated with bigger adaptation in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Blight Res. 11, 5878–5885 (2005).
Tokumo, M. et al. Double alteration and gene archetype cardinal of EGFR in gefitinib adverse non-small-cell lung cancer. Lung Blight 53, 117–121 (2006).
Tomizawa, Y. et al. Clinicopathologic acceptation of the mutations of the epidermal advance agency receptor gene in patients with non-small corpuscle lung cancer. Clin. Blight Res. 11, 6816–6822 (2005).
Zhang, X. T. et al. The EGFR alteration and its alternation with acknowledgment of gefitinib in ahead advised Chinese patients with avant-garde non-small-cell lung cancer. Ann. Oncol. 16, 1334–1342 (2005).
Jackman, D. M. et al. Exon 19 abatement mutations of epidermal advance agency receptor are associated with abiding adaptation in non-small corpuscle lung blight patients advised with gefitinib or erlotinib. Clin. Blight Res. 12, 3908–3914 (2006).
Riely, G. J. et al. Analytic advance of patients with non-small corpuscle lung blight and epidermal advance agency receptor exon 19 and exon 21 mutations advised with gefitinib or erlotinib. Clin. Blight Res. 12, 839–844 (2006).
Tokumo, M. et al. The accord amid epidermal advance agency receptor mutations and clinicopathologic appearance in non-small corpuscle lung cancers. Clin. Blight Res. 11, 1167–1173 (2005).
Hirsch, F. R. et al. Added epidermal advance agency receptor gene archetype cardinal detected by fluorescence in situ admixture assembly with added acuteness to gefitinib in patients with bronchioloalveolar blight subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838–6845 (2005).
Cappuzzo, F. et al. Added HER2 gene archetype cardinal is associated with acknowledgment to gefitinib assay in epidermal advance agency receptor-positive non-small-cell lung blight patients. J. Clin. Oncol. 23, 5007–5018 (2005).
Cappuzzo, F. et al. HER3 genomic accretion and acuteness to gefitinib in avant-garde non-small-cell lung blight patients. Br. J. Blight 93, 1334–1340 (2005).
Suzuki, R. et al. A appearance II abstraction of single-agent gefitinib as first-line assay in patients with date IV non-small-cell lung cancer. Br. J. Blight 94, 1599–1603 (2006).
Inoue, A. et al. Prospective appearance II abstraction of gefitinib for chemotherapy-naive patients with avant-garde non-small-cell lung blight with epidermal advance agency receptor gene mutations. J. Clin. Oncol. 24, 3340–3346 (2006).
Hirsch, F. R. et al. Atomic predictors of aftereffect with gefitinib in a appearance III placebo-controlled abstraction in avant-garde non-small-cell lung cancer. J. Clin. Oncol. 24, 5034–42 (2006).
Thatcher, N. et al. Gefitinib added best admiring affliction in ahead advised patients with adverse avant-garde non-small-cell lung cancer: after-effects from a randomised, placebo-controlled, multicentre abstraction (Iressa Adaptation Appraisal in Lung Cancer). Lancet 366, 1527–1537 (2005). Reports on a appearance III analytic balloon that showed a abridgement of adaptation annual in individuals with avant-garde NSCLC who were advised with gefitinib.
Ono, M. et al. Acuteness to gefitinib (Iressa, ZD1839) in non-small corpuscle lung blight corpuscle curve correlates with assurance on the epidermal advance agency (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt alleyway for proliferation. Mol. Blight Ther. 3, 465–472 (2004).
Han, S. W. et al. Epidermal advance agency receptor (EGFR) after molecules as acknowledgment predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small corpuscle lung cancer. Int. J. Blight 113, 109–115 (2005).
Mukohara, T. et al. Differential furnishings of gefitinib and cetuximab on non-small-cell lung cancers address epidermal advance agency receptor mutations. J. Natl Blight Inst. 97, 1185–1194 (2005).
Anderson, N. G., Ahmad, T., Chan, K., Dobson, R. & Bundred, N. J. ZD1839 (Iressa), a atypical epidermal advance agency receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the advance of EGFR-positive blight corpuscle curve with or after erbB2 overexpression. Int. J. Blight 94, 774–782 (2001).
Moasser, M. M., Basso, A., Averbuch, S. D. & Rosen, N. The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the advance of HER2-overexpressing bump cells. Blight Res. 61, 7184–7188 (2001).
She, Q. B., Solit, D., Basso, A. & Moasser, M. M. Attrition to gefitinib in PTEN-null HER-overexpressing bump beef can be affected through apology of PTEN action or pharmacologic accentuation of basal phosphatidylinositol 3′-kinase/Akt alleyway signaling. Clin. Blight Res. 9, 4340–4346 (2003).
Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase action in gefitinib-sensitive non-small corpuscle lung blight corpuscle lines. Proc. Natl Acad. Sci. USA 102, 3788–3793 (2005). Gefitinib acuteness is activated with the heterodimerization of EGFR with ERBB2 and the abrasion of Akt activation in gefitinib-treated NSCLC corpuscle lines.
Weinstein, I. B. Disorders in corpuscle chip during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857–864 (2000).
Sharma, S. V. et al. A accepted signaling avalanche may underlie ‘addiction’ to the Src, BCR-ABL, and EGF receptor oncogenes. Blight Corpuscle 10, 425–435 (2006). Details the atomic mechanistic base for blight corpuscle killing by oncogene-targeted therapeutics.
Evan, G. & Littlewood, T. A amount of action and corpuscle death. Science 281, 1317–1322 (1998).
Chen, C. Y. & Faller, D. V. Direction of p21ras-generated signals appear corpuscle advance or apoptosis is bent by protein kinase C and Bcl-2. Oncogene 11, 1487–1498 (1995).
Mayo, M. W. et al. Requirement of NF-κB activation to abolish p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812–1815 (1997).
Johnson, D. et al. Adjustment of both apoptosis and corpuscle adaptation by the v-Src oncoprotein. Corpuscle Afterlife Differ. 7, 685–696 (2000).
Webb, B. L., Jimenez, E. & Martin, G. S. v-Src generates a p53-independent apoptotic signal. Mol. Cell. Biol. 20, 9271–9280 (2000).
Wang, J. Y. Adjustment of corpuscle afterlife by the Abl tyrosine kinase. Oncogene 19, 5643–5650 (2000).
Reginato, M. J. et al. Integrins and EGFR coordinately adapt the pro-apoptotic protein Bim to anticipate anoikis. Nature Corpuscle Biol. 5, 733–740 (2003).
Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Corpuscle 69, 119–128 (1992).
Shi, Y. et al. Role for c-myc in activation-induced apoptotic corpuscle afterlife in T corpuscle hybridomas. Science 257, 212–214 (1992).
White, E. & Stillman, B. Announcement of adenovirus E1B aberrant phenotypes is abased on the host corpuscle and on amalgam of E1A proteins. J. Virol. 61, 426–435 (1987).
Rodenhuis, S. et al. Mutational activation of the K-ras oncogene. A accessible pathogenetic agency in adenocarcinoma of the lung. N. Engl. J. Med. 317, 929–935 (1987).
Mitsudomi, T. et al. ras gene mutations in non-small corpuscle lung cancers are associated with beneath adaptation irrespective of assay intent. Blight Res. 51, 4999–5002 (1991).
Husgafvel-Pursiainen, K. et al. K-ras mutations in animal adenocarcinoma of the lung: affiliation with smoker and anatomic acknowledgment to asbestos. Int. J. Blight 53, 250–256 (1993).
Ahrendt, S. A. et al. Cigarette smoker is acerb associated with alteration of the K-ras gene in patients with primary adenocarcinoma of the lung. Blight 92, 1525–1530 (2001).
Soung, Y. H. et al. Mutational assay of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 446, 483–488 (2005).
Pao, W. et al. KRAS mutations and primary attrition of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005). Shows the alternation amid the attendance of activated KRAS with NSCLC aloofness to EGFR-TKIs.
Cully, M., You, H., Levine, A. J. & Mak, T. W. Beyond PTEN mutations: the PI3K alleyway as an integrator of assorted inputs during tumorigenesis. Nature Rev. Blight 6, 184–192 (2006).
Kohno, T., Takahashi, M., Manda, R. & Yokota, J. Inactivation of the PTEN/MMAC1/TEP1 gene in animal lung cancers. Genes Chromosomes Blight 22, 152–156 (1998).
Soria, J. C. et al. Abridgement of PTEN announcement in non-small corpuscle lung blight could be accompanying to apostle methylation. Clin. Blight Res. 8, 1178–1184 (2002).
Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing bump beef counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812–2822 (2003).
Chakravarti, A., Loeffler, J. S. & Dyson, N. J. Insulin-like advance agency receptor I mediates attrition to anti-epidermal advance agency receptor assay in primary animal glioblastoma beef through connected activation of phosphoinositide 3-kinase signaling. Blight Res. 62, 200–207 (2002).
Hurbin, A., Dubrez, L., Coll, J. L. & Favrot, M. C. Inhibition of apoptosis by amphiregulin via an insulin-like advance factor-1 receptor-dependent alleyway in non-small corpuscle lung blight corpuscle lines. J. Biol. Chem. 277, 49127–49133 (2002).
Erjala, K. et al. Signaling via ErbB2 and ErbB3 assembly with attrition and epidermal advance agency receptor (EGFR) addition with acuteness to EGFR inhibitor gefitinib in arch and close squamous corpuscle blight cells. Clin. Blight Res. 12, 4103–4111 (2006).
Cappuzzo, F. et al. Insulin-like advance agency receptor 1 (IGFR-1) is decidedly associated with best adaptation in non-small-cell lung blight patients advised with gefitinib. Ann. Oncol. 17, 1120–1127 (2006).
Kosaka, T. et al. Assay of epidermal advance agency receptor gene alteration in patients with non-small corpuscle lung blight and acquired attrition to gefitinib. Clin. Blight Res. 12, 5764–5769 (2006).
Engelman, J. A. et al. Allelic concoction obscures apprehension of a biologically cogent attrition alteration in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695–2706 (2006).
Bell, D. W. et al. Inherited susceptibility to lung blight may be associated with the T790M biologic attrition alteration in EGFR. Nature Genet. 37, 1315–1316 (2005). Shows that the T790M alteration that confers acquired attrition to EGFR-TKIs ability additionally activate individuals to advance NSCLC.
Shih, J. Y., Gow, C. H. & Yang, P. C. EGFR alteration appointment primary attrition to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 353, 207–208 (2005).
Gorre, M. E. et al. Analytic attrition to STI-571 blight assay acquired by BCR-ABL gene alteration or amplification. Science 293, 876–880 (2001).
Blencke, S. et al. Characterization of a conserved structural annual authoritative protein kinase acuteness to careful inhibitors. Chem. Biol. 11, 691–701 (2004).
Daub, H., Specht, K. & Ullrich, A. Strategies to affected attrition to targeted protein kinase inhibitors. Nature Rev. Biologic Discov. 3, 1001–1010 (2004).
Zhou, B. B. et al. Targeting ADAM-mediated ligand break to arrest HER3 and EGFR pathways in non-small corpuscle lung cancer. Blight Corpuscle 10, 39–50 (2006).
Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N. & Nishio, K. Establishment of a animal non-small corpuscle lung blight corpuscle band aggressive to gefitinib. Int. J. Blight 116, 36–44 (2005).
Haber, D. A. & Settleman, J. Overcoming acquired attrition to Iressa/Tarceva with inhibitors of a altered class. Corpuscle Aeon 4, 1057–1059 (2005).
Elkind, N. B. et al. Multidrug agent ABCG2 prevents bump corpuscle afterlife induced by the epidermal advance agency receptor inhibitor Iressa (ZD1839, Gefitinib). Blight Res. 65, 1770–1777 (2005).
Ozvegy-Laczka, C., Cserepes, J., Elkind, N. B. & Sarkadi, B. Tyrosine kinase inhibitor attrition in cancer: role of ABC multidrug transporters. Biologic Resist. Updat. 8, 15–26 (2005).
Yanase, K. et al. Gefitinib reverses breast blight attrition protein-mediated biologic resistance. Mol. Blight Ther. 3, 1119–1125 (2004).
Nakamura, Y. et al. Gefitinib (‘Iressa’, ZD1839), an epidermal advance agency receptor tyrosine kinase inhibitor, reverses breast blight attrition protein/ABCG2-mediated biologic resistance. Blight Res. 65, 1541–1546 (2005).
Nagashima, S. et al. BCRP/ABCG2 levels annual for the attrition to topoisomerase I inhibitors and changeabout furnishings by gefitinib in non-small corpuscle lung cancer. Blight Chemother. Pharmacol. 58, 594–600 (2006).
Kitazaki, T. et al. Gefitinib, an EGFR tyrosine kinase inhibitor, anon inhibits the action of P-glycoprotein in multidrug aggressive blight cells. Lung Blight 49, 337–343 (2005).
Yang, C. H. et al. Gefitinib reverses chemotherapy attrition in gefitinib-insensitive multidrug aggressive blight beef cogent ATP-binding cassette ancestors protein. Blight Res. 65, 6943–6949 (2005).
Singh, J. et al. Structure-based architecture of a potent, selective, and irreversible inhibitor of the catalytic area of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130–1135 (1997).
Fry, D. W. et al. Specific, irreversible inactivation of the epidermal advance agency receptor and erbB2, by a new chic of tyrosine kinase inhibitor. Proc. Natl Acad. Sci. USA 95, 12022–12027 (1998).
Rabindran, S. K. et al. Antitumor action of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Blight Res. 64, 3958–3965 (2004).
Wissner, A. et al. Amalgam and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The architecture of an orally active, irreversible inhibitor of the tyrosine kinase action of the epidermal advance agency receptor (EGFR) and the animal epidermal advance agency receptor-2 (HER-2). J. Med. Chem. 46, 49–63 (2003).
Haber, D. A. et al. Atomic targeted assay of lung cancer: EGFR mutations and acknowledgment to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 419–426 (2005).
Discafani, C. M. et al. Irreversible inhibition of epidermal advance agency receptor tyrosine kinase with in vivo action by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387, 785). Biochem. Pharmacol. 57, 917–925 (1999).
Smaill, J. B. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal advance agency receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides address added solubilizing functions. J. Med. Chem. 43, 1380–1397 (2000).
Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011–11016 (2005). Details the development of added bearing TKIs that affected attrition that arises from mutations of the attendant balance in assorted tyrosine kinase oncogenes.
Shimamura, T. et al. Non-small-cell lung blight and Ba/F3 adapted beef harboring the ERBB2 G776insV_G/C alteration are acute to the dual-specific epidermal advance agency receptor and ERBB2 inhibitor HKI-272. Blight Res. 66, 6487–6491 (2006).
Ji, H. et al. Epidermal advance agency receptor alternative III mutations in lung tumorigenesis and acuteness to tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 103, 7817–7822 (2006).
Shimamura, T., Lowell, A. M., Engelman, J. A. & Shapiro, G. I. Epidermal advance agency receptors harboring kinase area mutations accessory with the calefaction shock protein 90 babysitter and are destabilized afterward acknowledgment to geldanamycins. Blight Res. 65, 6401–6408 (2005).
Yang, S. et al. Affiliation with HSP90 inhibits Cbl-mediated down-regulation of aberrant epidermal advance agency receptors. Blight Res. 66, 6990–6997 (2006).
Ge, J. et al. Design, synthesis, and biological appraisal of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 49, 4606–4615 (2006).
Herbst, R. S., Fukuoka, M. & Baselga, J. Gefitinib–a atypical targeted access to alleviative cancer. Nature Rev. Blight 4, 956–965 (2004).
Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour corpuscle growth. Nature 441, 424–430 (2006).
Ihle, N. T. et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes attrition to the epidermal advance agency receptor inhibitor gefitinib in A-549 animal non-small corpuscle lung blight xenografts. Mol. Blight Ther. 4, 1349–1357 (2005).
Fan, Q. W. et al. A bifold PI3 kinase/mTOR inhibitor reveals appearing ability in glioma. Blight Corpuscle 9, 341–349 (2006).
Goudar, R. K. et al. Aggregate assay of inhibitors of epidermal advance agency receptor/vascular endothelial advance agency receptor 2 (AEE788) and the beastly ambition of rapamycin (RAD001) offers bigger glioblastoma bump advance inhibition. Mol. Blight Ther. 4, 101–112 (2005).
Rao, R. D. et al. Disruption of alongside and advancing signaling pathways contributes to the accessory antitumor furnishings of accompanying mTOR and EGFR inhibition in GBM cells. Neoplasia 7, 921–929 (2005).
Doherty, L. et al. Pilot abstraction of the aggregate of EGFR and mTOR inhibitors in alternate cancerous gliomas. Neurology 67, 156–158 (2006).
Easton, J. B. & Houghton, P. J. Ameliorative abeyant of ambition of rapamycin inhibitors. Expert Opin. Ther. Targets 8, 551–564 (2004).
Margolin, K. et al. CCI-779 in metastatic melanoma: a appearance II balloon of the California Blight Consortium. Blight 104, 1045–1048 (2005).
Takeuchi, H. et al. Accessory accession of rapamycin-induced autophagy in cancerous glioma beef by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Blight Res. 65, 3336–3346 (2005).
Hay, N. The Akt-mTOR tango and its appliance to cancer. Blight Corpuscle 8, 179–183 (2005).
Adjei, A. A. Atypical combinations based on epidermal advance agency receptor inhibition. Clin. Blight Res. 12, 4446s–4450s (2006).
Hennequin, L. F. et al. Atypical 4-anilinoquinazolines with C-7 basal ancillary chains: architecture and anatomy action accord of a alternation of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 45, 1300–1312 (2002).
Wedge, S. R. et al. ZD6474 inhibits vascular endothelial advance agency signaling, angiogenesis, and bump advance afterward articulate administration. Blight Res. 62, 4645–4655 (2002).
Ciardiello, F. et al. Antitumor action of ZD6474, a vascular endothelial advance agency receptor tyrosine kinase inhibitor, in animal blight beef with acquired attrition to antiepidermal advance agency receptor therapy. Clin. Blight Res. 10, 784–793 (2004).
Taguchi, F. et al. Anticancer furnishings of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (‘Iressa’)-sensitive and aggressive xenograft models. Blight Sci. 95, 984–989 (2004).
Traxler, P. et al. AEE788: a bifold ancestors epidermal advance agency receptor/ErbB2 and vascular endothelial advance agency receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Blight Res. 64, 4931–4941 (2004).
Lee, D. Appearance II abstracts with ZD6474, a small-molecule kinase inhibitor of epidermal advance agency receptor and vascular endothelial advance agency receptor, in ahead advised avant-garde non-small-cell lung cancer. Clin. Lung Blight 7, 89–91 (2005).
Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004).
Sjoblom, T. et al. The accord coding sequences of animal breast and colorectal cancers. Science 314, 268–274 (2006). Highlights the abiogenetic complication and inter-tumour airheadedness of animal cancers.
Ngo, V. N. et al. A loss-of-function RNA arrest awning for atomic targets in cancer. Nature 441, 106–110 (2006). New approaches to anticancer ambition discovery.
Weinstein, I. B. Cancer. Addiction to oncogenes–the Achilles alleviate of cancer. Science 297, 63–64 (2002).
Weinstein, I. B. & Joe, A. K. Mechanisms of disease: Oncogene addiction-a account for atomic targeting in blight therapy. Nature Clin. Pract. Oncol. 3, 448–457 (2006).
Druker, B. J. et al. Furnishings of a careful inhibitor of the Abl tyrosine kinase on the advance of Bcr-Abl absolute cells. Nature Med. 2, 561–566 (1996).
Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
Fisher, G. H. et al. Induction and apoptotic corruption of lung adenocarcinomas by adjustment of a K-Ras transgene in the attendance and absence of bump suppressor genes. Genes Dev. 15, 3249–3262 (2001).
Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Corpuscle 4, 199–207 (1999).
Felsher, D. W. Blight revoked: oncogenes as ameliorative targets. Nature Rev. Blight 3, 375–380 (2003).
Shigematsu, H. & Gazdar, A. F. Actual mutations of epidermal advance agency receptor signaling alleyway in lung cancers. Int. J. Blight 118, 257–262 (2006).
Balak, M. N. et al. Atypical D761Y and accepted accessory T790M mutations in epidermal advance agency receptor-mutant lung adenocarcinomas with acquired attrition to kinase inhibitors. Clin. Blight Res. 12, 6494–6500 (2006).
Asahina, H. et al. Non-responsiveness to gefitinib in a accommodating with lung adenocarcinoma accepting attenuate EGFR mutations S768I and V769L. Lung Blight 54, 419–422 (2006).
Baselga, J. et al. Appearance I safety, pharmacokinetic, and pharmacodynamic balloon of ZD1839, a careful articulate epidermal advance agency receptor tyrosine kinase inhibitor, in patients with bristles called solid bump types. J. Clin. Oncol. 20, 4292–4302 (2002).
Janmaat, M. L., Kruyt, F. A., Rodriguez, J. A. & Giaccone, G. Acknowledgment to epidermal advance agency receptor inhibitors in non-small corpuscle lung blight cells: bound antiproliferative furnishings and absence of apoptosis associated with assiduous action of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Blight Res. 9, 2316–2326 (2003).
Tracy, S. et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung blight corpuscle band H3255. Blight Res. 64, 7241–7244 (2004).
Why You Should Not Go To Form I 3 Spanish Translation | Form I 3 Spanish Translation – form i 485 spanish translation
| Allowed for you to the website, with this time I will provide you with about keyword. And from now on, this is actually the 1st picture: